期刊
FRONTIERS IN PHARMACOLOGY
卷 6, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2015.00244
关键词
high-density lipoprotein (HDL); apolipoprotein A-1 (Apokl); sepsis; lipopolysaccharide (LPS); sepsis therapy
资金
- R01GM113832 [NIGMS/NIH]
- ALIA [13SDG17230049]
- NTH [T32 GM008353]
High density lipoprotein (HDL) is a key component of circulating blood and plays essential roles in regulation of vascular endothelial function and immunity. Clinical data demonstrate that HDL levels drop by 40-70% in septic patients, which is associated with a poor prognosis. Experimental studies using Apolipoprotein A-I (ApoAl) null mice showed that HDL deficient mice are susceptible to septic death, and overexpressing ApoAl in mice to increase HDL levels protects against septic death. These clinical and animal studies support our hypothesis that a decrease in HDL level is a risk factor for sepsis, and raising circulating HDL levels may provide an efficient therapy for sepsis. In this review, we discuss the roles of HDL in sepsis and summarize the efforts of using synthetic HDL as a potential therapy for sepsis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据